

论著

低氧对人脐带间充质干细胞活性和内皮分化能力的影响及VEGF的干预作用

李鹏¹, 周长勇¹, 尹磊¹, 孟宪琴¹, 张丽娜²

1. 青岛大学医学院附属医院急诊内科, 山东 青岛 266003;
2. 青岛大学医学院附属医院眼科, 山东 青岛 266003

摘要:

目的: 探讨低氧对人脐带间充质干细胞(hUC-MSCs)的活性及向内皮细胞分化能力的影响, 并进一步探索外源性VEGF对低氧损伤的保护作用。方法: 在体外对hUC-MSCs进行分离培养。对hUC-MSCs的形态学和表型特征进行分析。在添加/不添加50 ng/mL VEGF的情况下, 对hUC-MSCs分别进行不同时间的低氧诱导后, 对细胞凋亡率、ROS生成及细胞增殖能力进行检测, 并对hUC-MSCs的内皮分化能力进行评估。结果: 低氧诱导早期(6, 12 h), hUC-MSCs的凋亡及ROS生成显著增加, 增殖能力显著下降; 晚期(24, 72 h), 细胞的增殖及凋亡水平与对照组间无明显差异; 高浓度(50 ng/mL)外源性VEGF抑制低氧诱导早期出现的凋亡增加及增殖下降; 外源性VEGF存在的情况下, 低氧诱导14 d, hUC-MSCs表达早期内皮细胞表型, 并能获得部分内皮细胞功能。结论: 低氧早期造成hUC-MSCs急性损伤, 晚期通过逐步适应恢复细胞活性并保持了其分化潜能。VEGF能够保护急性缺氧对细胞的损伤, 并能诱导其向内皮样细胞分化。

关键词: 间充质干细胞 低氧 血管内皮生长因子 分化 细胞凋亡 增殖

Role of hypoxia in viability and endothelial differentiation potential of UC-MSCs and VEGF interference

LI Peng¹, ZHOU Changyong¹, YIN Lei¹, MENG Xianqin¹, ZHANG Lina²

1. Department of Emergency Room, the Affiliated Hospital of Medical College, Qingdao University, Qingdao Shandong 266003, China;
2. Department of Ophthalmology, the Affiliated Hospital of Medical College, Qingdao University, Qingdao Shandong 266003, China

Abstract:

Objective: To investigate the effect of hypoxia on cell viability and the endothelial differentiation potential in human umbilical cord derived mesenchymal stem cells (UC-MSCs), and to assess the in vitro protective role of VEGF under low oxygen tension.

Methods: MSCs were isolated from human umbilical cords and cultured in vitro. The morphological and phenotypic characterizations of human UC-MSCs were analyzed. The hypoxia induction was performed with or without the presence of 50 ng/mL of VEGF for different lengths of time. The cell proliferation, apoptosis, and reactive oxygen species (ROS) generation were assessed. Meanwhile, the endothelial differentiation potential of the UC-MSCs was measured.

Results: An increased apoptosis and ROS generation but reduced proliferation rate were observed at early stages (6, 12 h) after transferring the UC-MSCs from the atmospheric condition to the hypoxia condition. However, the UC-MSCs presented equal proliferation and apoptosis levels under hypoxic condition as compared with those under the atmospheric condition at the later stages (24, 72 h). A high concentration of exogenous VEGF (50 ng/mL) attenuated the increased apoptosis and inhibited the proliferation of UC-MSCs, induced by a short-term hypoxia treatment. After 14 days of exogenous VEGF induction under the hypoxia condition, the UC-MSCs acquired an early endothelial phenotype consisting of a mature endothelial molecule and some endothelial functions.

Conclusion: UC-MSCs progressively adapt to hypoxia in a step-by-step manner and maintain differentiation potential under hypoxia condition. VEGF can protect the UC-MSCs from cell damage and induce a differentiation of UC-MSCs toward endothelial lineage under hypoxic conditions.

扩展功能

本文信息

- Supporting info
- PDF(2083KB)
- [HTML全文]
- 参考文献[PDF]
- 参考文献

服务与反馈

- 把本文推荐给朋友
- 加入我的书架
- 加入引用管理器
- 引用本文
- Email Alert
- 文章反馈
- 浏览反馈信息

本文关键词相关文章

- 间充质干细胞
- 低氧
- 血管内皮生长因子
- 分化
- 细胞凋亡
- 增殖

本文作者相关文章

- 李鹏
- 周长勇
- 尹磊
- 孟宪琴
- 张丽娜

PubMed

- Article by LI Peng
- Article by ZHOU Changyong
- Article by YIN Lei
- Article by MENG Xianqin
- Article by ZHANG Lina

Keywords: mesenchymal stem cells hypoxia VEGF differentiation apoptosis proliferation

收稿日期 2012-05-18 修回日期 网络版发布日期

DOI: 10.3969/j.issn.1672-7347.2013.04.001

基金项目:

通讯作者: ZHANG Lina, Email: zhanglina1105@163.com

作者简介: LI Peng, master, attending doctor, mainly engaged in the research of stem cell therapy for cardiovascular diseases.

作者Email: zhanglina1105@163.com

参考文献:

1. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells [J]. *Science*, 1999, 284(5411): 143-147.
2. Ren G, Chen X, Dong F, et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues [J]. *Stem Cells Transl Med*, 2012, 1(1):51-58.
3. Batsali AK, Kastrinaki MC, Papadaki HA, et al. Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications [J]. *Curr Stem Cell Res Ther*, 2013, 8(2): 144-155.
4. Lee KD. Applications of mesenchymal stem cells: an updated review [J]. *Chang Gung Med J*, 2008, 31(3): 228-236.
5. Harrop JS, Hashimoto R, Norvell D, et al. Evaluation of clinical experience using cell-based therapies in patients with spinal cord injury: a systematic review [J]. *J Neurosurg Spine*, 2012, 17(1): 230-246.
6. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells [J]. *Ann N Y Acad Sci*, 2009, 1176(9): 101-117.
7. Wang D, Chen K, Du WT, et al. CD14+ monocytes promote the immunosuppressive effect of human umbilical cord matrix stem cells [J]. *Exp Cell Res*, 2010, 316(15): 2414-2423.
8. Shetty P, Cooper K, Viswanathan C. Comparison of proliferative and multilineage differentiation potentials of cord matrix, cord blood, and bone marrow mesenchymal stem cells [J]. *Asian J Transfus Sci*, 2010, 4(1): 14-24.
9. Troyer DL, Weiss ML. Wharton's jelly-derived cells are a primitive stromal cell population [J]. *Stem Cells*, 2008(26): 591-599.
10. Li DR, Cai JH. Methods of isolation, expansion, differentiating induction and preservation of human umbilical cord mesenchymal stem cells [J]. *Chin Med J*, 2012, 125(24): 4504-4510.
11. Chen MY, Lie PC, Li ZL, et al. Endothelial differentiation of Wharton's jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells [J]. *Exp Hematol*, 2009, 37(5): 629-640.
12. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord [J]. *Stem Cells*, 2004, 22(7): 1330-1337.
13. Shi RZ, Li QP. Improving outcome of transplanted mesenchymal stem cells for ischemic heart disease [J]. *Biochem Biophys Res Commun*, 2008, 376(2): 247-250.
14. Belmokhtar K, Bourguignon T, Worou ME, et al. Regeneration of three layers vascular wall by using BMP2-treated MSC involving HIF-1 α and Id1 expressions through JAK/STAT pathways [J]. *Stem Cell Rev*, 2011, 7(4): 847-859.
15. Lavrentieva A, Majore L, Kasper C, et al. Effects of hypoxic culture conditions on umbilical cord-derived human mesenchymal stem cells [J]. *Cell Commun Signal*, 2010, 8(7): 18.
16. Potier E, Ferreira E, Andriamanalijaona R, et al. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression [J]. *Bone*, 2007, 40(4): 1078-1087.
17. Holzwarth C, Vaegler M, Gieseke F, et al. Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells [J]. *BMC Cell Biology*, 2010, 11(1): 11.
18. Oswald J, Boxberger S, Jørgensen B, et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro [J]. *Stem Cells*, 2004, 22(3): 377-384.
19. Gang EJ, Jeong JA, Han S, et al. In vitro endothelial potential of human UC blood-derived

- mesenchymal stem cells [J] . *Cytotherapy*, 2006, 8(3): 215-227.
20. Pons J, Huang Y, Arakawa-Hoyt J, et al. VEGF improves survival of mesenchymal stem cells in infarcted hearts [J] . *Biochem Biophys Res Commun*, 2008, 376(2): 419-422.
21. Zisa D, Shabbir A, Suzuki G, et al. Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repair [J] . *Biochem Biophys Res Commun*, 2009, 390(3): 834-838.
22. Lu LL, Liu YJ, Yang SG, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials [J] . *Haematologica*, 2006, 91(8): 1017-1026.
23. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J] . *Cytotherapy*, 2006, 8(4): 315-317.
24. Short B, Brouard N, Occhiodoro-Scott T, et al. Mesenchymal stem cells [J] . *Arch Med Res*, 2003, 34(6): 565-571.
25. Pikir BS, Susilowati H, Hendrianto E, et al. Reversin increase the plasticity of bone marrow-derived mesenchymal stem cell for generation of cardiomyocyte in vitro [J] . *Acta Med Indones*, 2012, 44(1): 23-27.
26. Harrop JS, Hashimoto R, Norvell D, et al. Evaluation of clinical experience using cell-based therapies in patients with spinal cord injury: a systematic review [J] . *J Neurosurg Spine*, 2012, 17(1): 230-246.
27. Wolf D, Reinhard A, Krause U, et al. Stem cell therapy improves myocardial perfusion and cardiac synchronicity: new application for echocardiography [J] . *J Am Soc Echocardiogr*, 2007, 20(5): 512-520.
28. Simpson DL, Boyd NL, Kaushal S, et al. Use of human embryonic stem cell derived-mesenchymal cells for cardiac repair [J] . *Biotechnol Bioeng*, 2012, 109(1): 274-283
29. Jackson WM, Nesti LJ, Tuan RS. Concise review: clinical translation of wound healing therapies based on mesenchymal stem cells [J] . *Stem Cells Transl Med*, 2012, 1(1): 44-50.
30. Zhang M, Methot D, Poppa V, et al. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies [J] . *J Mol Cell Cardiol*, 2001, 33(5): 907-921.
31. Zhu W, Chen J, Cong X, et al. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells [J] . *Stem Cells*, 2006, 24(2): 416-425.
32. Ren H, Cao Y, Zhao Q, et al. Proliferation and differentiation of bone marrow stromal cells under hypoxic conditions [J] . *Biochem Biophys Res Commun*, 2006, 347(1): 12-21.
33. 孔霞, 郑飞, 郭凌郢, 等. VEGF通过细胞外信号调节激酶途径促进骨髓源间充质干细胞的增殖 [J] . *中国实验血液学杂志*, 2010, 18(5): 1292-1296. KONG Xia, ZHENG Fei, GUO Lingyun, et al. VEGF promotes the proliferation of bone marrow derived mesenchymal stem cells through ERK1/2 signal pathway [J] . *Journal of Experimental Hematology*, 2010, 18(5): 1292-1296.
34. Buravkova LB, Andreeva ER, Grigor'ev AI. The impact of oxygen tension in physiological regulation of human multipotent mesenchymal stromal cell functions [J] . *Fiziol Cheloveka*, 2012, 38(4): 121-130.
35. Vieira HL, Alves PM, Vercelli A. Modulation of neuronal stem cell differentiation by hypoxia and reactive oxygen species [J] . *Prog Neurobiol*, 2011, 93(3): 444-455.
36. Lin RZ, Wang TP, Hung RJ, et al. Tumor-induced endothelial cell apoptosis: roles of NAD(P)H oxidase-derived reactive oxygen species [J] . *J Cell Physiol*, 2011, 226(7): 1750-1762.
37. Lendahl U, Lee KL, Yang H, et al. Generating specificity and diversity in the transcriptional response to hypoxia [J] . *Nat Rev Genet*, 2009, 10(12): 821-832.
38. Dos Santos F, Andrade PZ, Boura JS, et al. Ex vivo expansion of human mesenchymal stem cells: a more effective cell proliferation kinetics and metabolism under hypoxia [J] . *J Cell Physiol*, 2010, 223(1): 27-35.
39. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors [J] . *Nat Med*, 2003, 9(6): 669-676.
40. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for FIK-1/KDR activation [J] . *J Biol Chem*, 1998, 273(46): 30336-30343.
41. Song YH, Gehmert S, Sadat S, et al. VEGF is critical for spontaneous differentiation of stem cells into cardiomyocytes [J] . *Biochem Biophys Res Commun*, 2007, 354(4): 999-